- Current report filing (8-K)
June 04 2012 - 7:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 4, 2012
Senesco Technologies, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
001-31326
|
84-1368850
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
721 Route 202-206, Suite 130, Bridgewater, NJ
|
08807
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(908) 864-4444
|
(Registrant's telephone number,
including area code)
|
|
Not applicable
(Former Name or Former Address, if Changed
Since Last Report)
|
|
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)).
|
Item 8.01 Other Events.
On June 4, 2012, Senesco Technologies,
Inc. (“Senesco”) issued a press release announcing the progress of its Phase 1b/2a study for the treatment of multiple
myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.
To date five patients have been enrolled
into the study. So far one patient has completed the 6 week dosing schedule. This patient’s disease was considered stable,
no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6. Two
patients were withdrawn from the study due to disease progression, and two patients are currently being treated. No disease limiting
toxicities have been recorded to date.
In the study, patients are dosed twice-weekly
for 6 weeks followed by an observation period. The first group of patients receives 0.0125 mg/kg by intravenous infusion. At the
end of 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher dosage. The
escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively.
The study is an open-label, multiple-dose,
dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to
approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective of this study is to evaluate safety
and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established
metrics including measurement of monoclonal protein.
A copy of this press release is
filed
as Exhibit 99.1 hereto and incorporated herein by reference.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release of Senesco Technologies, Inc. dated June 4, 2012.
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
|
SENESCO TECHNOLOGIES, INC.
|
|
|
|
|
Dated: June 4, 2012
|
By:
/s/ Leslie J. Browne, Ph.D.
|
|
Name: Leslie J. Browne, Ph.D.
|
|
Title: President and Chief Executive Officer
|
Senesco (AMEX:SNT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Oct 2023 to Oct 2024